加载中
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
常规交易时段
US$3.745
−US$0.125 · -3.23%
盘中时间采用ET。市场数据可能有所延迟。
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
日内区间
当前US$3.745
52周区间
当前US$3.745
盘中时间采用ET。市场数据可能有所延迟。
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
日内区间
当前US$3.745
52周区间
当前US$3.745
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1429万 USD | 3657.1万 USD | 3213万 USD | 3173.7万 USD | 2381.8万 USD |
| 销售、一般及管理费用 | 579.5万 USD | 586.2万 USD | 594.2万 USD | 661.5万 USD | 636.1万 USD |
| 营业费用 | 2008.5万 USD | 4243.3万 USD | 3807.2万 USD | 3835.2万 USD | 3017.9万 USD |
| 利息收入 | 12.6万 USD | 33.8万 USD | 23万 USD | 5.2万 USD | 3000 USD |
| 利息支出 | 732.9万 USD | 554万 USD | 279.2万 USD | 103.3万 USD | 48.9万 USD |
| 折旧和摊销 | 5.3万 USD | 3.7万 USD | 3.3万 USD | 3.2万 USD | 4.1万 USD |
| 营业利润 | −2008.5万 USD | −4243.3万 USD | −3807.2万 USD | −3835.2万 USD | −3017.9万 USD |
| 净利润 | −3083.6万 USD | −4704.7万 USD | −4106.6万 USD | −3877.6万 USD | −3052.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$11.00
上涨空间 193.72%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2012年3月23日 | 1:6 | — | — |
已生效 2012年3月23日
1:6
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI600.97万0.00%2.3万亿 USD0.03%US$380.46-0.29%
iShares Russell 2000 ETFIWM455.3万0.01%787.4亿 USD0.19%US$275.96-0.70%
Vanguard Extended Market ETFVXF246.28万0.00%954亿 USD0.05%US$231.54-0.85%
iShares Russell 2000 Growth ETFIWO119.46万0.01%139.17亿 USD0.24%US$349.95-1.06%
Vanguard Russell 2000 ETFVTWO108.81万0.01%180亿 USD0.06%US$111.46-0.73%
iShares Russell 2000 Value ETFIWN60万—137.49亿 USD0.24%US$210.42-0.32%
iShares Micro-Cap ETFIWC58.16万0.04%13.17亿 USD0.60%US$179.88-0.98%
Horizon Kinetics Medical ETFMEDX16.43万0.99%1656.51万 USD0.85%US$34.9692-0.80%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNiShares Micro-Cap ETFIWCHorizon Kinetics Medical ETFMEDXAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
